Clinilabs, Inc., a specialty contract research organization (CRO), has completed expansion of its Phase I unit.
CLINILABS EXPANDS PHASE I FACILITY
New York, NY (August 6, 2008) – Clinilabs, Inc., a specialty contract research organization (CRO), has completed expansion of its Phase I unit. This expansion brings the Company’s Phase I facility to 68-beds, which includes two new large observation rooms that can accommodate up to four beds each, or up to 12 PK seats.
The Company conducts Phase I studies in any therapeutic area, including pharmacokinetic (PK), pharmacodynamic (PD), bioavailability (BA), bioequivalence (BE), drug interaction, and food interaction studies. Additionally, Clinilabs offers specialty services for complex PD studies, such as those that involve the collection of mood, cognition, psychomotor functioning, EEG, quantitative EEG, evoked potential (EP), and imaging data.
“Phase I studies are becoming increasingly complex and sponsors depend on data from these studies to make crucial decisions about their development programs,” stated Dr. Gary Zammit, President and CEO of Clinilabs. “Clinilabs’ state-of-the-art facility is an ideal location for pharmaceutical and biotechnology companies looking for outstanding service for their Phase I studies,” he added.
Conveniently located in New York City, Clinilabs can recruit patients from a large and diverse population, including healthy adult, healthy elderly, Japanese, Chinese, and key patient populations. In addition, Clinilabs’ metropolitan location provides sponsors, as well as patients, with easy access to transportation hubs and major subway and bus lines.
Clinilabs Phase I facility is staffed with highly qualified physicians, nurses, and research associates, providing service 24 hours a day, 7 days a week.
About Clinilabs, Inc.
Clinilabs is a specialty contract research organization (CRO) that provides a full portfolio of services to pharmaceutical, biotechnology, and medical device companies involved in the development of central nervous system (CNS) and cardiovascular (CV) therapeutics. The Company also provides early phase services in a wider range of therapeutic areas at its Phase I facility. Established in 2001, Clinilabs has provided services to more than one third of the world’s top 20 pharmaceutical companies, and has been involved in 7 successful New Drug Applications (NDAs) in central nervous system (CNS) and cardiovascular (CV) indications. For more information, please visit www.clinilabs.com <
http://www.clinilabs.com/
> .
Zenocutuzumab Shows Durable Efficacy in NRG1 Fusion-Positive Cancers in Phase II eNRGy Trial
February 13th 2025The Phase II eNRGy trial showed durable antitumor activity with zenocutuzumab (Bizengri) in patients with NRG1 fusion–positive cancers, particularly non-small cell lung cancer and pancreatic cancer.
Behind the Buzz: Why Clinical Research Leaders Flock to SCOPE Summit
February 7th 2025In this episode, we meet with Micah Lieberman, Executive Conference Director for SCOPE Summit (Summit for Clinical Ops Executives) at Cambridge Innovation Institute. We will dive deep into the critical role of collaboration within the clinical research ecosystem. How do we bring together diverse stakeholders—sponsors, CROs, clinical trial tech innovators, suppliers, patients, sites, advocacy organizations, investors, and non-profits—to share best practices in trial design, program planning, innovation, and clinical operations? We’ll explore why it’s vital for thought leaders to step beyond their own organizations and learn from others, exchanging ideas that drive advancements in clinical research. Additionally, we’ll discuss the pivotal role of scientific conferences like SCOPE Summit in fostering these essential connections and collaborations, helping shape the future of clinical trials. Join us as we uncover how collective wisdom and cross-industry partnerships are transforming the landscape of clinical research.
Reaching Diverse Patient Populations With Personalized Treatment Methods
January 20th 2025Daejin Abidoye, head of solid tumors, oncology development, AbbVie, discusses a number of topics around diversity in clinical research including industry’s greatest challenges in reaching diverse patient populations, personalized treatment methods, recruitment strategies, and more.
SCOPE Summit 2025: Enhancing the Patient Experience Through Site Centricity
February 12th 2025In an interview with ACT senior editor Andy Studna at SCOPE Summit, Ashley Davidson, vice president, product lead - sponsor tech strategy, Advarra, highlights the need for more site-centric approaches in study startup.